What is the current stock price of Annexon, Inc. (ANNX)?

As of the latest market data, Annexon, Inc. (ANNX) is trading at $5.85. The stock has seen a loss of -4.72% today.

Does Annexon, Inc. (ANNX) pay a dividend?

Based on current data, Annexon, Inc. does not have a confirmed active dividend policy.

What is the market cap of Annexon, Inc.?

The current market capitalization of Annexon, Inc. (ANNX) is approximately unavailable.

ANNX

Annexon, Inc.·Healthcare

5.85

4.723%(−0.29)

Market Closed

6.59

12.650%(+0.74)

After Hours

Last Updated: — ET

52W L: $1.4052W H: $7.18

ANNX NEWS

globenewswire.com

2d ago

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq.

zacks.com

Apr 1

Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?

The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

globenewswire.com

Mar 30

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA

globenewswire.com

Mar 16

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

defenseworld.net

Mar 5

Annexon, Inc. (NASDAQ:ANNX) Receives $17.00 Average Target Price from Analysts

Annexon, Inc. (NASDAQ: ANNX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The

globenewswire.com

Feb 24

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq.

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Sector

Healthcare

Industry

Biotechnology

Employees

106

IPO Date

2020-07-24

Beta

1.15

Websitewww.annexonbio.com↗